AVITA Medical (RCEL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does AVITA Medical (RCEL) do?
AVITA Medical Inc (RCEL) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures single-use medical kits that prepare regenerative skin cell suspensions directly in hospital operating rooms. It uses a point-of-care medical device to prepare sprayable autologous skin cells from a small patient biopsy. It is worth $397.19M on the market and sold $84.69M over the last year.
- Market cap
- $397.19M
- P/E ratio
- None (reported a loss)
- Annual sales
- $84.69M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 18, 2026
Brands and businesses behind RCEL
- RECELL: Sells single-use devices that process patient skin biopsies into sprayable regenerative cell suspensions for wound healing.
- RECELL GO: Provides automated enzyme-based skin cell processing hardware and cartridges to hospitals treating severe wounds.
RCEL’s flags, in plain English
Each flag is a number from AVITA Medical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 82.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 38.1% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Burning Cash
Losing money, profit margin of -42.7%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about RCEL
How big is AVITA Medical?
AVITA Medical’s market cap is $397.19M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $84.69M: what customers paid the company over the last year, before any costs.
What is RCEL’s P/E ratio?
RCEL has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with RCEL?
Revenue depends almost entirely on the commercial adoption of the RECELL product line in a small number of specialized burn centers. That is one risk on AVITA Medical’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From AVITA Medical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RCEL’s filings on SEC.gov. The Margin Monkey is research, not advice.
